Clinical Trials Directory

Trials / Unknown

UnknownNCT03477721

The Role of the Muscle-nervous System Interface in Cancer Cachexia

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
University of Roma La Sapienza · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers

Summary

Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which can result in better therapeutic interventions to reverse this situation and improve the prognosis. Our hypothesis is that the plasma concentration of IL-6 and c-terminal agrin is directly correlated with the loss of muscle mass and development of cachexia.

Detailed description

The agrin is a protein that acts on neuromuscular junctions (NMJs) promoting stabilization of same, which results in the maintenance and growth of muscle fibers, but the cleavage of agrin, a process by which is formed the agrin fragment C-terminus (CAF), has been linked to the development of sarcopenia, because its presence is directly linked to the reduction in the number of muscle fibers, increasing the heterogeneity of fiber size, presence of Central cores and increasing the proportion of type I fibers and consequently a greater degradation of lean body mass. Studies in mice show that the greatest cleavage of agrin carries on development of sarcopenia and human studies report that individuals with higher serum levels of sarcopenia CAF compared to individuals without sarcopenia. Therefore, aiming at the complexity of cancer associated with the cachexia and the great importance of the maintenance of lean body mass to a better prognosis in disease, is of fundamental importance to elucidate the role of CAF and the factors associated with sarcopenia, the possible use of these proteins for diagnosis and the contribution that this clarification could bring in clinical therapy.

Conditions

Timeline

Start date
2018-03-16
Primary completion
2018-04-16
Completion
2018-04-30
First posted
2018-03-26
Last updated
2018-03-26

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03477721. Inclusion in this directory is not an endorsement.